Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -7 of 7 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				Hx-CD20-406 NCT00349349


2.		HuMax-CD20 in FL Patients Refractory to Rituximab

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				Hx-CD20-405 NCT00394836


3.		Ofatumumab-Chlorambucil Combination vs. Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Approved-not yet active				18 and over				Pharmaceutical / Industry				OMB110911 EudraCT 2008-004932-19, NCT00748189


4.		Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				Hx-CD20-407 NCT00410163


5.		Ofatumumab (Humax-CD20) With CHOP in FL Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				Hx-CD20-409 NCT00494780


6.		Ofatumumab in Patients With Relapsed Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapsed After Transplant

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				GEN415 NCT00622388


7.		Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				20 to 79				Pharmaceutical / Industry				OMB111148 NCT00742144

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute